Payment overview · 2025
General Payments
$3,125.42
136 reported records · 18 companies
Healthcare provider profile · identity verified
Jared Andre, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CHICAGO, IL · NPI 1528470291
Verified facts
What the public records show
CMS Open Payments records show Jared Andre, M.D. received $3,125.42 in general payments during 2025 across 136 reported records.
ABBVIE INC. accounted for 28.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Paxlovid, Rybelsus, Synthroid, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $888.86 | 28.4% | 42 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $761.50 | 24.4% | 28 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $269.57 | 8.6% | 12 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $249.74 | 8.0% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $217.27 | 7.0% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $172.02 | 5.5% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $137.94 | 4.4% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $95.71 | 3.1% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $65.11 | 2.1% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $46.67 | 1.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $41.24 | 1.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $37.92 | 1.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $28.58 | 0.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $28.31 | 0.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.78 | 0.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.59 | 0.7% | 1 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $21.34 | 0.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.27 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,125.42 | 136 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $478.90 | 17 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $456.44 | 17 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $337.17 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $318.65 | 19 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $249.74 | 13 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $235.98 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $232.61 | 15 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $212.22 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $193.73 | 8 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $83.74 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $77.24 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $73.69 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $71.89 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $71.89 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $71.89 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.34 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $70.34 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $65.11 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $64.95 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $48.73 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.98 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $46.67 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $46.67 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $41.24 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $37.92 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $28.31 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.59 | 1 | 2025 |
Source payment records
|
|||||
| BD Onclarity Normalized: bd onclarity |
Device | Becton, Dickinson and Company | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 92 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 55 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 74 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 75 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
75 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 603 | 166 |
| Lisinopril | Lisinopril | 370 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 107 |
| Losartan Potassium | Losartan Potassium | 266 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 261 | 74 |
| Oxycodone Hcl | Oxycodone Hcl | 258 | 34 |
| Gabapentin | Gabapentin | 247 | 53 |
| Metformin Hcl | Metformin Hcl | 214 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 180 | 47 |
| Omeprazole | Omeprazole | 168 | 50 |
| Simvastatin | Simvastatin | 164 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 45 |
| Prednisone | Prednisone | 132 | 94 |
| Lorazepam | Lorazepam | 128 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 125 | 15 |
| Furosemide | Furosemide | 109 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 28 |
| Diazepam | Diazepam | 97 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 30 |
| Montelukast Sodium | Montelukast Sodium | 95 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 24 |
| Tramadol Hcl | Tramadol Hcl | 95 | 19 |
| Eliquis | Apixaban | 92 | 26 |
| Sertraline Hcl | Sertraline Hcl | 91 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 26 |
| Alprazolam | Alprazolam | 84 | 17 |
| Allopurinol | Allopurinol | 82 | 23 |
| Trazodone Hcl | Trazodone Hcl | 81 | 24 |
| Ozempic | Semaglutide | 75 | 13 |
| Valsartan | Valsartan | 75 | 24 |
| Clonazepam | Clonazepam | 74 | 12 |
| Mounjaro | Tirzepatide | 74 | suppressed |
| Ibuprofen | Ibuprofen | 71 | 18 |
| Atenolol | Atenolol | 70 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 59 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 13 |
| Glipizide Er | Glipizide | 57 | 18 |
| Pregabalin | Pregabalin | 56 | suppressed |
| Jardiance | Empagliflozin | 55 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 12 |
| Azithromycin | Azithromycin | 53 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 15 |
| Metformin Hcl Er | Metformin Hcl | 50 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 18 |
| Spironolactone | Spironolactone | 50 | 16 |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Trulicity | Dulaglutide | 47 | 13 |
| Famotidine | Famotidine | 44 | 17 |
| Hydromorphone Hcl | Hydromorphone Hcl | 43 | suppressed |
| Chlorthalidone | Chlorthalidone | 40 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Finasteride | Finasteride | 37 | 11 |
| Potassium Chloride | Potassium Chloride | 37 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Carvedilol | Carvedilol | 35 | 11 |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 11 |
| Meloxicam | Meloxicam | 32 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 17 |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 11 |
| Torsemide | Torsemide | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 17 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Rybelsus | Semaglutide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,125.42 · 136 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BD Onclarity, BREZTRI, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, GVOKE HYPOPEN, IBSRELA, JARDIANCE, Kerendia, LEQVIO, LINZESS, M-M-R II, MOUNJARO, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SYNTHROID, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error